ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $24.00 Average PT from Analysts

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have earned an average rating of “Moderate Buy” from the seventeen brokerages that are covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $24.00.

ACAD has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $23.00 to $20.00 in a report on Friday, January 3rd.

Institutional Trading of ACADIA Pharmaceuticals

Large investors have recently modified their holdings of the stock. Values First Advisors Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $27,000. Virtus Fund Advisers LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $39,000. R Squared Ltd acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $47,000. Quest Partners LLC grew its position in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $64,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $19.01 on Friday. The company has a 50 day simple moving average of $18.28 and a 200 day simple moving average of $16.78. The firm has a market cap of $3.16 billion, a PE ratio of 24.37 and a beta of 0.37. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $26.56.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.